135 related articles for article (PubMed ID: 37149430)
1. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
Spratte BN; Tan HJ; Zambrano IA; Basak RS; Filson CP; Jacobs BL; Hwang S
Urol Oncol; 2023 Jul; 41(7):323.e17-323.e25. PubMed ID: 37149430
[TBL] [Abstract][Full Text] [Related]
2. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.
Hoffman RM; Mott SL; McDowell BD; Anand ST; Nepple KG
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):100-108. PubMed ID: 34108645
[TBL] [Abstract][Full Text] [Related]
3. Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.
Whalen MJ; Pak JS; Lascano D; Ahlborn D; Matulay JT; McKiernan JM; Benson MC; Wenske S
Clin Genitourin Cancer; 2018 Apr; 16(2):e425-e435. PubMed ID: 29113772
[TBL] [Abstract][Full Text] [Related]
4. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
5. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
6. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
7. Active treatment in low-risk prostate cancer: a population-based study.
Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
[TBL] [Abstract][Full Text] [Related]
8. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
9. Expectant management of veterans with early-stage prostate cancer.
Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
[TBL] [Abstract][Full Text] [Related]
10. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
Monfared S; Fleishman A; Korets R; Chang P; Wagner A; Bubley G; Kaplan I; Olumi AF; Gershman B
Urol Oncol; 2021 Nov; 39(11):783.e21-783.e30. PubMed ID: 33992521
[TBL] [Abstract][Full Text] [Related]
13. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
14. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
Eifler JB; Alvarez J; Koyama T; Conwill RM; Ritch CR; Hoffman KE; Resnick MJ; Penson DF; Barocas DA;
J Urol; 2017 Mar; 197(3 Pt 1):614-620. PubMed ID: 27984110
[TBL] [Abstract][Full Text] [Related]
15. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract][Full Text] [Related]
16. Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer.
Dell'Oglio P; Boehm K; Trudeau V; Tian Z; Larcher A; Leyh-Bannurah SR; Moschini M; Capitanio U; Shariat SF; Briganti A; Montorsi F; Saad F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1037-1045. PubMed ID: 27478167
[TBL] [Abstract][Full Text] [Related]
17. Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
Beatrici E; Labban M; Stone BV; Filipas DK; Reis LO; Lughezzani G; Buffi NM; Kibel AS; Cole AP; Trinh QD
Eur Urol; 2023 Dec; 84(6):527-530. PubMed ID: 37758573
[TBL] [Abstract][Full Text] [Related]
18. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
[TBL] [Abstract][Full Text] [Related]
19. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
20. Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance.
Zambrano IA; Hwang S; Basak R; Spratte BN; Filson CP; Jacobs BL; Tan HJ
Urol Oncol; 2023 Sep; 41(9):388.e1-388.e8. PubMed ID: 37286404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
